Compound Detail
CHEMBL1372
OXIGLUTATIONE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
Basic Information
| ChEMBL ID | CHEMBL1372 |
| Name | OXIGLUTATIONE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | YPZRWBKMTBYPTK-BJDJZHNGSA-N |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
10
Publications
4
Known Names
5
Indications
1
Mechanisms
Molecular Properties
612.6
MW (Da)
-3.88
ALogP
12
HBA
10
HBD
317.6
PSA (Ų)
0.04
QED
3
Ro5 Violations
21
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1982 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Glutathione reductase other | OTHER | Glutathione reductase, mitochondrial | ✓ | ✓ |
Indications
Carcinoma, Non-Small-Cell Lung Breast Neoplasms Leukemia Myelodysplastic Syndromes Ovarian Neoplasms
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 19223619 | 10.1128/aac.01449-08 | Helicobacter pylori | 8 |
| 20014752 | 10.1021/tx900326k | Hepatotoxicity | 3 |
| 29519735 | 10.1016/j.bmcl.2018.02.043 | Histone-lysine N-methyltransferase EHMT1 | 2 |
| 29519735 | 10.1016/j.bmcl.2018.02.043 | Histone-lysine N-methyltransferase EHMT2 | 2 |
| 15537352 | 10.1021/jm0497545 | Glutathione reductase | 1 |
| 18457386 | 10.1021/jm7015683 | ATP-binding cassette sub-family C member 2 | 1 |
| 19193010 | 10.1021/jm801389m | Multidrug resistance-associated protein 1 | 1 |
| - | 10.1101/2020.04.03.023846 | SARS-CoV-2 | 1 |
| 32608236 | 10.1021/acs.jmedchem.9b02119 | Sialin | 1 |
| 36518699 | 10.1021/acsmedchemlett.2c00450 | 14 kDa phosphohistidine phosphatase | 1 |
Data from ChEMBL 36 via Core Engine